Amarin Co. plc Given New $11.00 Price Target at JPMorgan Chase & Co. (AMRN)
Equities researchers at JPMorgan Chase & Co. lowered their price target on shares of Amarin Co. plc (NASDAQ:AMRN) from $12.00 to $11.00 in a research report issued on Friday, Analyst Ratings Network reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price objective suggests a potential upside of 66.67% from the company’s current price.
AMRN has been the subject of a number of other recent research reports. Analysts at Aegis reiterated a “buy” rating on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note to investors on Friday. They now have a $30.00 price target on the stock. Separately, analysts at SunTrust initiated coverage on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note to investors on Wednesday, September 4th. They set a “buy” rating on the stock. Finally, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note to investors on Monday, August 12th. They now have a $11.00 price target on the stock, down previously from $13.00.
Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $13.54.
Amarin Co. plc (NASDAQ:AMRN) remained flat at $6.60 during during mid-day trading trading on Friday. 3,239,026 shares of the company’s stock traded hands. Amarin Co. plc has a 52 week low of $5.12 and a 52 week high of $14.80. The stock’s 50-day moving average is $6.00 and its 200-day moving average is $6.70. The company’s market cap is $1.139 billion.
Amarin Co. plc (NASDAQ:AMRN) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. Analysts expect that Amarin Co. plc will post $-1.36 EPS for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.